Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer-Reference-Cited by-同舟云学术

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

Published:2017-08-11 Issue:10 Volume:7 Page:1168-1183
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Haricharan Svasti,Punturi Nindo,Singh Purba,Holloway Kimberly R.,Anurag Meenakshi,Schmelz Jacob,Schmidt Cheryl,Lei Jonathan T.,Suman Vera,Hunt Kelly,Olson John A.,Hoog Jeremy,Li Shunqiang,Huang Shixia,Edwards Dean P.,Kavuri Shyam M.,Bainbridge Matthew N.,Ma Cynthia X.,Ellis Matthew J.

Funder

Susan G. Komen

CPRIT

NCINIHNIH

Siteman Cancer Center

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD4⁺Foxp3E2⁺regulatory T cell frequency predicts breast cancer prognosis and recurrence;2024-09-07

2. Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies;Cancer Treatment Reviews;2024-09

3. Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence;2024-03-02

4. An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy;Biomedicines;2024-02-22

5. The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility;Critical Reviews in Oncology/Hematology;2023-12